2004 Annual Meeting | Women's Issues in Epilepsy

��ɫ��

2004 Annual Meeting | Women's Issues in Epilepsy

Date Wednesday 04/28/04

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Andrew G. Herzog, MD, MSc, FAAN

Topic(s) Epilepsy/Clinical Neurophysiology (EEG)

Learning Objectives Upon completion:
Participants should be able to describe molecular biological mechanisms by which neurosteroids influence neuronal excitability and seizures; understand the role of reproductive steroids in catamenial epilepsy and the potential use of hormones in seizure management; know the effects of epilepsy and antiepileptic drugs on contraception, fertility and pregnancy; and deal effectively with menopause as it may affect seizures and bone density issues in women with epilepsy.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
02:15 PM - 03:00 PM		Neurosteroids and Epilepsy Michael A. Rogawski, MD, PhD
03:00 PM - 03:45 PM		Catamenial Epilepsy and Hormonal Therapy Andrew G. Herzog, MD, MSc, FAAN
03:45 PM - 04:00 PM		Break
04:00 PM - 04:45 PM		Management of Pregnancy in Women With Epilepsy Mark S. Yerby, MD, MPH, FAAN
04:45 PM - 05:30 PM		Menopause and Bone Density Issues in Women With Epilepsy Cynthia L. Harden, MD
05:30 PM - 06:00 PM		Discussion

Faculty Disclosures
Cynthia L. Harden, MD	Dr. Harden has received personal compensation for serving as an employee of Xenon Pharmaceuticals Inc.. Dr. Harden has stock in Xenon Pharmaceuticals Inc.. Dr. Harden has received intellectual property interests from a discovery or technology relating to health care.
Andrew G. Herzog, MD, MSc, FAAN	Dr. Herzog has nothing to disclose.
Michael A. Rogawski, MD, PhD	Dr. Rogawski has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Xenon Pharmaceuticals.
Mark S. Yerby, MD, MPH, FAAN	No disclosure on file
	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��